Pulmonary Arterial Hypertension
Patients with PAH show more benefit with seralutinib if deemed responders
Among patients with pulmonary arterial hypertension treated with 72-week seralutinib, those deemed responders had more improved measures, according to a poster presented at the Pulmonary Vascular Research Institute 2025 Annual Congress.
Winrevair PAH trial stopped due to earlier ‘robust evidence’
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous trials, according to a press release.
Most-read FDA actions from 2024 in pulmonology
Healio Pulmonology has compiled the top news from the FDA posted in 2024.
Q&A: Trial to investigate PAH monotherapy vs. dual therapy in pediatric patients
There has been little research on optimal treatments for pediatric patients with pulmonary arterial hypertension, but the Kids MoD PAH Trial is expected to change this by clearing up if sildenafil plus bosentan or sildenafil only is better.
Awareness of pulmonary hypertension in patients with COPD growing
PHILADELPHIA — With the 2025 GOLD report newly featuring a section dedicated to pulmonary hypertension, it is important that clinicians expand their knowledge of this comorbidity, according to a presentation.
New EULAR systemic sclerosis recommendations illuminate a ‘significantly changed’ field
EULAR has released new recommendations on the treatment of systemic sclerosis, advancing new treatments and updated approaches to key manifestations such as skin and lung fibrosis.
Topline results: Winrevair lowers risk for mortality in patients with advanced PAH
Adults with pulmonary arterial hypertension functional class three or four faced a decreased risk for all-cause mortality or morbidity events with Winrevair vs. placebo, according to phase 3 ZENITH trial topline results.
Treatment in PAH similar with, without mental health comorbidities
BOSTON — Having pulmonary arterial hypertension plus a mental health comorbidity did not result in differing treatments or outcomes from those without this comorbidity, according to data presented at the CHEST Annual Meeting.
Sodium-glucose inhibitor use in PAH may have mortality benefit
BOSTON — Fewer patients with pulmonary arterial hypertension died at three time points with use of a sodium-glucose cotransporter-2 inhibitor, according to data presented at the CHEST Annual Meeting.
PAH, right ventricular hypertrophy prevalent in patients with ILD
BOSTON — Among patients with interstitial lung disease, 30% had pulmonary arterial hypertension and 20% had right ventricular hypertrophy, according to data presented at the CHEST Annual Meeting.